<DOC>
	<DOCNO>NCT01443442</DOCNO>
	<brief_summary>Allergic conjunctivitis ( AC ) afflict approximately 20 % US population . Typically , patient manifest symptom spring , summer fall , airborne allergen peak . Patients may also afflict year-round , sensitive allergen dust mite pet dander . Signs symptoms allergic conjunctivitis conjunctival hyperemia , ocular itching , conjunctival eyelid edema , papillary hypertrophy , tear burning . This randomized clinical study evaluate efficacy Bepreve® ( bepotastine besilate 1.5 % ophthalmic solution ) compare Alrex® ( loteprednol etabonate 0.2 % ) treatment moderate severe allergic conjunctivitis patient age 18 year . The study two-week study four visit . Ocular sign ( eye redness ( symptom ( itch ) monitor outcome variable .</brief_summary>
	<brief_title>Bepreve vs. Alrex Subjects With Moderate Severe Allergic Conjunctivitis</brief_title>
	<detailed_description>Investigator Study Center : Judy Tong , OD Eye Care Center Southern California College Optometry Test Product , Dose Mode Administration : Bepreve ( bepotastine besilate ophthalmic solution ) 1.5 % bid ou vs. Alrex ( loteprednol etabonate ophthalmic suspension ) 0.2 % qid ou Study Title : A Single-Center , Masked , Randomized Study Comparing Bepreve ( bepotastine besilate ) 1.5 % - H1 Specific Antihistamine vs. Alrex ( loteprednol etabonate ) 0.2 % - Corticosteroid Subjects Moderate Severe Allergic Conjunctivitis Primary Objective ( ) : The primary objective study compare efficacy Bepreve ( bepotastine besilate ) 1.5 % ophthalmic solution compare Alrex ( loteprednol etabonate ) 0.2 % treatment moderate severe allergic conjunctivitis patient age 18 year age Study Design : Interventional , Randomized , Parallel Arm , Investigator Masked Study Population : Subjects age 18 year age moderate severe allergic conjunctivitis . Duration Treatment : 14 day Efficacy Assessments : Itching , Bulbar conjunctival injection , Bulbar conjunctival chemosis Safety Assessments : N/A</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Moderate severe allergic subject ( ≥ 2.5 0.0 4.0 itch scale AND &gt; grade 2.0 bulbar redness use validate ( Efron ) scale ) Must able understand sign inform consent form approve Institutional Review Board ( IRB ) . Can comply instillation study drug Must able comply visit schedule requirement study . Subjects use daily wear ( 57 day / week , 616 hours/day ) 25 disposable soft hydrogel silicone hydrogel contact lenses include study consistently wear brand use care solution one month longer . They ask wear soft contact lenses eligibility visit ( three day lens wear ) willing discontinue lens wear two week study incompatibility medicate eye drop instillation contact lens wear potential confounding effect contact lenses care solution . Active inflammation cornea , iris , anterior chamber Active suspect herpetic eye disease ( simplex , vaccinia , varicella ) Active suspect mycobacterial acanthamoeba infection Active suspect fungal disorder eye Persistent significant dry eye syndrome Known allergy , contraindication hypersensitivity loteprednol , bepotastine , component Pregnancy breastfeed Use topical eye drop , topical systemic antihistamine , topical , nasal systemic corticosteroid , immunosuppressive immunomodulating agent , decongestant , aspirin , nonsteroidal antiinflammatory ( NSAIDs ) two week prior study . Participation study within 30 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Conjunctivitis</keyword>
	<keyword>Allergic</keyword>
	<keyword>Bepotastine besilate</keyword>
	<keyword>Loteprednol etabonate</keyword>
</DOC>